Proprietary intraoperative data for HIPEC.
Hayhurst Medical Technologies, LLC is developing a medical device for use during hyperthermic intraperitoneal chemotherapy (HIPEC) — the highest-mortality subspecialty in surgical oncology. The device captures multi-zone intraoperative pressure telemetry, generating a new class of clinical data without existing precedent.
30–60% of patients recur after cytoreductive surgery + HIPEC despite optimal cytoreduction. 87% of recurrences concentrate in three anatomical zones (mesentery, pelvis, abdominal wall); 78% arise at surgically damaged peritoneum where current delivery fails.
Peer-reviewed evidence (Mouw et al., Surgery 2022; Cooney et al., J Gastrointest Oncol 2024) establishes the underlying mechanism and the "cold pockets" problem the device addresses.
HMT is following a proprietary instrumentation strategy: hardware-locked data acquisition feeding a multi-stream platform spanning device sales, AI-derived clinical decision support, pharma real-world evidence partnerships, and sponsored research. Multi-zone HIPEC pressure telemetry is the missing instrumentation layer in a clinical domain with no proprietary intraoperative dataset.
Joseph L. Hayhurst, MD — physician-founder. Completed three years of general surgery training. Muscogee (Creek) Nation citizen. MD from the University of Oklahoma College of Medicine.
Christopher Camarata, MD — Founding CTO. Completed six years of general surgery residency, where he trained alongside HMT's CEO. Foundation model and AI infrastructure expertise. Leads data architecture and AI platform development.
Mazin Alkasspooles, MD — Senior Clinical Advisor. Retired CRS/HIPEC surgical oncologist; 30+ years practice; established in the academic peritoneal surface malignancy community.
Regulatory pathway and engineering partnership under active review. Additional advisor profiles available on request under mutual confidentiality once formal engagements are executed.